Sovereign Nations. Different Laws. One Complicated Payments System.
Sovereign Nations. Different Laws. One Complicated Payments System. On Indigenous Peoples' Day, it's time to examine why tribal gaming, ...
The Food and Drug Administration has weathered nine months of unprecedented turbulence in 2025, yet drug approval numbers tell a surprisingly stable story. Despite the exodus of senior leadership, staffing reductions, and high-profile controversies, the agency has maintained approval rates consistent with recent years—a testament to institutional resilience that offers important lessons for companies operating in highly regulated sectors.
The FDA's 2025 trajectory reads like a case study in organizational crisis management. More than half the agency's senior leadership departed their positions. The workforce contracted by 3,500 employees. A safety scandal disrupted the gene therapy sector, culminating in the removal and subsequent surprising return of CBER Director Vinay Prasad. These disruptions would destabilize most organizations, yet the agency's core regulatory functions continued operating within normal parameters.
Jefferies analysts counted 28 total approvals through August 25, 2025, across the Center for Drug Evaluation and Research and Center for Biologics Evaluation and Research. Extrapolating to year-end, they projected 43 approvals—a figure squarely within the 37 to 68 range observed over the previous five years. This consistency prompted analysts to conclude that fears of a dysfunctional FDA may be overblown, noting that the agency's actions year-to-date have not signaled a more stringent or irrational regulatory posture.
Andrew Tsai, Jefferies analyst, emphasized this point directly: the analysis revealed nothing drastically alarming or different compared to prior years. For pharmaceutical companies, contract manufacturers, and related industries, this consistency provides reassurance that regulatory processes remain predictable despite surface-level chaos.
The implications extend beyond pharmaceutical manufacturers to adjacent industries including nutraceuticals, dietary supplements, and botanical products. When the FDA maintains operational consistency during internal disruption, it demonstrates that regulatory infrastructure can withstand personnel changes without compromising review standards. Companies in regulated sectors should take note: robust quality management systems similarly must maintain operational integrity regardless of internal staffing changes, leadership transitions, or external pressures.
Rejected drug applications trended lower than the previous year through August, with CDER on pace to issue fewer complete response letters compared to the past five years. This suggests that either companies are submitting higher-quality applications or that FDA reviewers are providing clearer guidance during development phases, allowing sponsors to address deficiencies before formal submissions.
However, CBER headed toward issuing more complete response letters, indicating different dynamics within the biologics space. This divergence between centers highlights that regulatory experiences can vary significantly depending on product type and reviewing division. Companies developing biological products face distinct challenges compared to those pursuing small molecule approvals.
The year delivered several surprising rejections that caught industry observers off guard. Capricor Therapeutics CEO Linda Marbán expressed shock when the company's cell therapy for Duchenne muscular dystrophy received a complete response letter in July, noting that the rejection was unexpected given the trajectory of positive interactions with the FDA. This disconnect between sponsor expectations and regulatory decisions underscores persistent challenges in interpreting FDA feedback accurately.
Similarly, twenty-two scientists who designed and ran trials for Replimune's advanced melanoma drug RP1 took the extraordinary step of writing an open letter urging the FDA to reconsider its July rejection. When researchers directly involved in clinical development feel compelled to publicly challenge regulatory decisions, it signals significant disagreement about evidence interpretation and approval standards.
Yet the system also demonstrated flexibility. Stealth BioTherapeutics successfully convinced the FDA to reconsider its May rejection of Barth syndrome drug Forzinity. After refiling in August, the company received expedited review and won accelerated approval less than a month later. This rapid reversal illustrates that the FDA remains responsive to compelling scientific arguments and can move quickly when evidence supports approval.
These examples reveal important quality management lessons. First, maintaining positive FDA interactions throughout development does not guarantee approval—companies must ensure that data packages unambiguously meet regulatory standards rather than relying on encouraging signals. Second, complete response letters are not necessarily terminal—strategic refiling with additional evidence or clarifications can lead to approval. Third, the timeline from refiling to approval can compress dramatically when data clearly address regulatory concerns.
FDA Commissioner Marty Makary identified accelerating rare disease therapies as a top priority upon taking office in April 2025. He floated the idea of a conditional approval pathway for such therapies in early media interviews, and the agency subsequently rolled out Rare Disease Evidence Principles—a new framework designed to streamline approvals for ultra-rare disease treatments.
The year 2025 has seen fourteen novel therapies approved for rare diseases, including treatments for alkaptonuria, recessive dystrophic epidermolysis bullosa, and phenylketonuria. These approvals suggest that the FDA is following through on stated priorities, particularly regarding expediting rare disease drugs.
However, seven rare disease therapies received complete response letters, some surprisingly given the policy emphasis on facilitating such approvals. This mixed record indicates that while the FDA has created pathways to accelerate rare disease drug development, sponsors still must meet evidentiary standards. Policy priorities do not translate to relaxed approval criteria—they simply mean that regulators will work more collaboratively with sponsors and accept appropriately flexible evidence packages.
For companies developing products in rare disease spaces—whether pharmaceuticals, nutraceuticals, or botanical therapies—this dynamic creates both opportunities and challenges. The opportunities lie in FDA willingness to engage early, accept innovative trial designs, and consider diverse evidence sources. The challenges involve ensuring that flexible approaches still generate data meeting regulatory standards for substantial evidence of effectiveness.
Quality management systems supporting rare disease product development must accommodate unique trial designs while maintaining rigorous data integrity standards. Small patient populations necessitate creative recruitment strategies, adaptive protocols, and potentially surrogate endpoints. Quality management platforms must track these complex methodologies while ensuring that flexibility never compromises data quality or patient safety.
The highest number of novel drug approvals in 2025 came from the oncology space, according to data collected by both BioSpace and Jefferies. This continues a longstanding pattern where cancer therapies dominate approval statistics. The concentration reflects several factors: high unmet medical need, willingness of regulators and sponsors to accept greater risks for life-threatening diseases, and substantial investment in oncology research and development.
Treatments for infectious diseases and autoimmune or immunological diseases also ranked high among 2025 FDA approvals. The infectious disease focus partly reflects ongoing attention to pandemic preparedness and antimicrobial resistance. Autoimmune and immunological therapies benefit from improved understanding of immune system mechanisms and development of targeted biologics that precisely modulate immune responses.
These therapeutic area concentrations carry implications for quality management strategies. Oncology products often involve complex biologics, antibody-drug conjugates, or cell therapies requiring sophisticated manufacturing processes and quality controls. Companies developing such products need quality management systems capable of handling sterile processing, complex analytics, and stringent contamination controls.
Infectious disease products may involve special considerations around containment, pathogen handling, and verification that manufacturing processes eliminate adventitious agents. Autoimmune therapies frequently employ biologic platforms requiring comprehensive characterization, process validation, and stability programs that track product quality throughout shelf life.
Quality management systems must adapt to the specific requirements of therapeutic areas where companies focus development efforts. Generic approaches that work for simple oral solids prove inadequate for complex biologics, cell therapies, or gene therapies. Organizations need quality platforms that can be configured to match the unique compliance requirements of their specific products and therapeutic areas.
Over the past twenty-five years, White House control has alternated between Republican and Democrat administrations multiple times. During three of those transitions, new FDA commissioners were installed during the administration's first year. Since drug approvals are not political decisions, one would not expect a flood of new drug approvals in the inaugural year of a new administration.
This pattern has generally held true, with one notable exception. In 2017, during President Trump's first term, when Scott Gottlieb took the reins from Robert Califf, the FDA approved 46 new drugs—more than double the number greenlit the previous year. This anomaly stands out against the backdrop of otherwise consistent approval patterns regardless of administration changes.
Steven Grossman, policy and regulatory consultant and author of the FDA Matters blog, notes that the last two years of an eight-year administration are not known for policymaking or starting new initiatives. However, this should not slow drug approvals or lead to surges in subsequent years. Indeed, in 2009, when Margaret Hamburg took the helm during President Obama's first year, the agency approved just one more novel drug than in 2008.
The results of 2025's changeover from Califf, who served a second stint as commissioner, to Makary remain to be determined. Through three quarters, approval rates track with historical averages, suggesting that the transition has not dramatically altered review processes or approval thresholds. Whether this consistency continues through year-end will provide additional data points for understanding how leadership changes affect regulatory operations.
For pharmaceutical and supplement companies, this historical pattern offers reassurance that regulatory processes generally transcend political transitions. While policy priorities may shift between administrations, the fundamental regulatory framework governing product approvals remains stable. Companies should focus on building quality management systems aligned with statutory requirements and scientific principles rather than attempting to time development programs around political cycles.
A potentially significant complication emerged on October 1, 2025, when the FDA announced it would be unable to accept any new drug applications until after the government shutdown was resolved. The agency cannot accept industry user fees assessed for 2026 during the lapse period, preventing new application acceptance.
This shutdown adds uncertainty to 2025's ultimate approval tally. Applications that would have been submitted in October cannot be accepted until the shutdown ends, potentially pushing some reviews into 2026. Whether this affects annual approval totals depends on shutdown duration and whether companies can submit applications quickly once the government reopens.
Beyond immediate numerical impacts, the shutdown highlights vulnerabilities in the regulatory system. Companies invest hundreds of millions developing products, plan submissions around specific dates to align with patent strategies or market dynamics, yet can face indefinite delays due to political dysfunction entirely unrelated to scientific or regulatory considerations.
Quality management implications are significant. Companies must build contingency plans addressing potential submission delays. These plans should cover extended product stability programs if commercial launch dates slip, communication strategies for clinical trial participants whose access to investigational products might be affected, and financial modeling that accounts for delayed revenue recognition.
The shutdown also emphasizes the importance of maintaining open communication channels with FDA reviewers. While formal submissions cannot be accepted during shutdowns, informal scientific discussions may continue depending on circumstances. Companies with strong FDA relationships and clear communication can better navigate disruptions and position themselves for rapid progress once normal operations resume.
The FDA's ability to maintain consistent approval rates despite internal upheaval offers valuable lessons for companies in pharmaceutical, nutraceutical, dietary supplement, and botanical product sectors. Robust quality management systems share characteristics with resilient regulatory agencies: they maintain operational integrity regardless of personnel changes, they document processes so thoroughly that institutional knowledge survives individual departures, and they establish standardized procedures that continue functioning even during leadership transitions.
Companies should examine their own quality management systems through this lens. If key quality personnel departed suddenly, could operations continue without interruption? If senior leadership changed, would quality standards remain consistent? If external pressures emerged, would compliance infrastructure hold firm? Organizations that answer these questions affirmatively have built quality systems with FDA-like institutional resilience.
Documentation standards become especially critical during transitions. The FDA maintains approval consistency partly because review processes are extensively documented, guided by formal guidance documents, and supported by standard operating procedures that reviewers follow regardless of political appointee preferences. Similarly, companies need comprehensive documentation ensuring that quality processes continue unchanged even as personnel evolve.
Training programs play equally important roles. The FDA invests heavily in reviewer training, ensuring that new staff understand approval standards and apply them consistently. Companies must similarly invest in training that ensures all personnel understand quality requirements, can execute procedures correctly, and maintain compliance standards without constant oversight.
Risk management takes on heightened importance when organizations face internal disruption. The FDA presumably conducted extensive risk assessments regarding how leadership departures and staffing reductions might affect core functions, then implemented mitigation strategies ensuring critical operations continued. Companies should similarly identify risks that personnel changes, resource constraints, or external pressures might pose to quality operations, then establish contingency plans addressing those risks before they materialize.
Pharmaceutical approvals through three quarters of 2025 demonstrates that well-designed regulatory systems can maintain functional consistency even during substantial organizational turmoil. This resilience should inspire companies developing products in regulated spaces to build similarly robust quality management infrastructure.
Centralized quality management platforms provide essential foundation for resilience. When quality documentation, training records, supplier data, risk assessments, and compliance monitoring information reside in centralized systems rather than scattered across individual computers or paper files, organizations maintain institutional memory regardless of personnel turnover. New employees can access comprehensive historical information, ensuring continuity of understanding about product development decisions, regulatory strategies, and quality standards.
Automated workflows reduce dependence on individual expertise by embedding quality processes into systems that guide users through required steps. When document approvals, change controls, and corrective actions follow automated sequences, companies ensure that critical quality activities occur consistently regardless of who executes them. This automation mirrors how FDA standard operating procedures guide reviewers through evaluation processes.
Real-time monitoring capabilities enable organizations to identify emerging quality issues before they compound into serious problems. Just as the FDA tracks metrics around review timelines, complete response letter rates, and approval patterns to identify potential process issues, companies should monitor quality indicators including supplier performance, deviation rates, corrective action effectiveness, and training compliance. These metrics provide early warning signals when quality systems show strain.
Supplier management deserves particular attention given its importance throughout product lifecycles. The FDA's consistency in approvals suggests that pharmaceutical companies are generally maintaining supply chain quality despite broader industry disruptions. Companies can replicate this success by implementing comprehensive supplier qualification processes, conducting regular performance evaluations, establishing clear quality agreements, and maintaining contingency suppliers for critical materials.
While the FDA has maintained approval consistency through 2025, the regulatory environment continues to evolve in ways that will shape compliance strategies for years to come. Commissioner Makary's emphasis on rare disease acceleration represents just one policy direction that will influence how companies approach product development and quality management.
The Rare Disease Evidence Principles framework signals FDA willingness to accept flexible evidence packages for ultra-rare conditions. Companies should understand these principles thoroughly and design development programs that leverage available flexibility while meeting evidentiary standards. Quality management systems must accommodate innovative trial designs, patient-reported outcomes, real-world evidence, and other approaches that the principles contemplate.
The divergence between CDER and CBER complete response letter rates suggests that biologics face distinct challenges compared to small molecules. Companies developing biological products should anticipate potentially closer scrutiny and ensure that quality systems address the unique complexities biologics present. This includes comprehensive analytical characterization, thorough process validation, robust stability programs, and extensive comparability studies when manufacturing changes occur.
The surprising rejections that occurred despite positive FDA interactions emphasize the importance of objective data assessment. Companies should regularly conduct internal reviews of development programs using the same critical lens FDA reviewers will apply. These reviews should identify data gaps, weaknesses in evidence packages, or analytical limitations before FDA encounters them. Quality management systems should facilitate these critical assessments by providing comprehensive visibility into all development data.
The government shutdown reminder underscores that external factors beyond scientific or regulatory considerations can affect timelines. Companies should build flexibility into development plans, maintain contingency strategies for submission timing, and establish robust communication channels with FDA that can help navigate unexpected disruptions.
The FDA's maintenance of consistent approval rates despite organizational upheaval demonstrates the power of robust regulatory infrastructure. Your organization needs equivalent resilience in its quality management systems—systems that maintain compliance regardless of personnel changes, external pressures, or unexpected disruptions.
Qredible provides quality management solutions specifically designed for highly regulated industries facing complex compliance demands. Our Q-Trust platform offers centralized documentation, automated workflows, real-time monitoring, and comprehensive supplier management capabilities that ensure your quality operations continue without interruption even during challenging circumstances. With systems designed for pharmaceutical, nutraceutical, dietary supplement, and botanical product companies, Qredible understands the unique compliance challenges your organization faces.
Whether you're developing rare disease therapies under new FDA frameworks, manufacturing complex biologics requiring sophisticated quality controls, or producing dietary supplements in an evolving regulatory environment, the quality management infrastructure you establish today determines your success tomorrow. Contact Qredible today to discover how our compliance solutions can help your organization build the regulatory resilience that enables consistent performance regardless of external circumstances. Get in Qredible and transform quality management from potential vulnerability into strategic advantage.
